Helicobacter pylori in children: think before you kill the bug!

Abstract

Since the discovery of Helicobacter pylori (H. pylori) as the causative organism for gastric and duodenal ulcers four decades ago and subsequent recognition as class 1 gastric carcinogen, countless numbers of studies have been conducted and papers published, on the efficacy of various management strategies to eradicate the infection. In adults, a global consensus by the experts in the field concluded that H. pylori gastritis is an infectious disease and requires treatment irrespective of the presence or absence of symptoms due to the potential for serious complication like peptic ulcer disease and gastric neoplasia. However, although more than half the world’s population harbors H. pylori, these serious complications occur only in a small minority of the infected population, even less so in childhood. More importantly, there is accumulating evidence for beneficial role of H. pylori against many chronic health conditions, from several epidemiological and laboratory studies. No doubt, eradication therapy is indicated in children with H. pylori-related peptic ulcer disease. Even though the pediatric guidelines from various learned societies recommend against a “test and treat” strategy, this is not always adhered to. With the accumulating evidence of the possible beneficial role of H. pylori, it is time to pause and think, are we causing more harm than good by eradicating H. pylori in every child who has this bug?

Keywords

Asthma and allergies benefits children eosinophilic esophagitis gastroesophageal reflux inflammatory bowel disease obesity

Introduction

Helicobacter pylori (H. pylori), a gram-negative bacterium that colonizes the gastric mucosa, is one of the most common gastrointestinal infections, infecting more than half the world’s population.¹ The prevalence varies from 24% to 73% depending on geographical region and economic development.² The infection is mostly acquired in childhood and persists for life in the infected host unless treated.³ Since the discovery of H. pylori by Warren and Marshall in 1983,⁴ its causative role in peptic ulcer disease (PUD) and gastric cancers is well established. Eradication of H. pylori heals the ulcer, reduces the ulcer recurrence,⁵ and might confer long-term protection against gastric cancer in high-risk populations.⁶ In addition, iron deficiency anemia^7–9 and idiopathic thrombocytopenic purpura¹⁰ are found to be strongly associated with the infection. There also appears to be growing interest in the potential role of H. pylori in other extragastric conditions including cardiovascular, respiratory, neurological, dermatological, and metabolic diseases.^11,12 An excellent recent review summarizes the extra gastric diseases associated with H. pylori.¹² With this background, various guidelines have evolved and updated by several professional bodies, endorsing testing and treating H. pylori infection in the adult population.^13–15

However, children are not little adults, and this is true with respect to H. pylori infection too. The prevalence is lower; children have a low rate of severe disease associated with H. pylori and almost an absence of gastric malignancies.¹⁶ Infection is generally asymptomatic in children. Several studies have shown a lack of evidence of relation between abdominal pain or other abdominal symptoms in children and H. pylori infection.^17–21 There is no evidence that eradication of H. pylori, in the absence of PUD, is beneficial in improvement of abdominal symptoms. In addition, there is increasing antibiotics resistance, particularly to Clarithromycin.^22–24

Recognizing these differences, pediatric guidelines from many learned societies including that from the European Society of Pediatric Gastroenterology Hepatology and Nutrition and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition on the management of H. pylori in Children recommend against a ‘test and treat strategy’. The primary goal of clinical investigation should be to identify the cause of abdominal symptoms rather than look for H. pylori infection.²⁵ Unfortunately, in real life, guidelines are not always adhered to.²⁶ It is all too common to see inappropriate tests (e.g., H. pylori serology or breath test) being used to diagnose the infection and any positive test leading to eradication treatment (authors personal experience). No doubt, eradication treatment should be done in children with PUD. What is not clear is whether treating H. pylori infection without PUD is beneficial at all. On the contrary, there is accumulating evidence that this may even be harmful, by exposing children to greater risks of various chronic conditions, as discussed in the following sections.

Method: Review of beneficial effects of H. pylori infection in children.

Asthma and allergies

The prevalence of allergic diseases and asthma had been increasing in many countries in recent decades,^27,28 which coincided with increased hygiene and socioeconomic conditions along with decrease in many infectious diseases.²⁹ The prevalence of H. pylori infection, both in children and adults, is decreasing in the western world as well as in some developing countries, as H. pylori-associated disease has led to aggressive diagnostic and eradication strategies. This contrasts with increase in childhood asthma and allergic diseases.^2,30–32 Though opposite prevalence trends of H. pylori infection and allergies have been reported, accumulating evidence supports an inverse relationship between H. pylori and the risk of asthma. After the first report by Chen and Blaser who found an inverse association between H. pylori seropositivity and asthma in children,³³ several studies and meta-analyses have confirmed this negative association. A recent meta-analysis of 18 observational studies reported the exact same conclusion that H. pylori infection, particularly CagA +ve infection, is inversely associated with the risk of childhood asthma. All 18 studies included in this analysis were of moderate to high quality and included a total of 17,196 children.³⁴ In a hospital-based case-control study, Elias et al. concluded that H. pylori infection and related gastric inflammation may have a protective role against pediatric asthma.³⁵ This inverse relationship with pediatric asthma is seen even in a high H. pylori prevalence population.³⁶ A recent cross-sectional study again demonstrated a significant inverse association between H. pylori infection and pediatric asthma.³⁷ There is also report that H. pylori not only protects against childhood asthma but also inversely correlates to its clinical and functional severity.³⁸ Chen et al. in their meta-analysis of 24 studies, which included both pediatric and adult subjects, concluded that the accumulated evidence supports that H. pylori infection (especially Cag A positive H. pylori) is inversely associated with the risk of asthma.³⁹

Similar to asthma, systematic reviews and meta-analyses have reported an inverse correlation of H. pylori infection with atopy.^40–43 Children, in particular, appear to benefit from their H. pylori infection in that the inverse correlation with allergy is strongest in pediatric cohorts.⁴⁰ Though causality is not proven in humans, animal studies have shown a direct protective effect of H. pylori via regulatory T cells (Tregs).^44–46

However, not all studies have demonstrated this inverse relationship with asthma. In their review of relevant surveys, cohort studies, meta-analyses, and studies testing the protective hypothesis of H. pylori against atopy, allergy, and asthma, Miftahussurur et al. reported that the meta-analyses showed a significant but weak inverse correlation, but studies directly testing the protection hypothesis in relation to asthma failed to confirm a protective effect⁴⁷

Eosinophilic esophagitis (EoE), a chronic immune-mediated inflammatory disease of the esophagus, is increasing in frequency.⁴⁸ Interestingly, large cross-sectional analyses of several populations have identified an inverse relationship with EoE and the presence of H. pylori.^49–51 In their comprehensive meta-analysis of 11 observational studies comprising data on 377,795 individuals worldwide, Shah et al. reported that exposure to H. pylori was associated with a 37% reduction in odds of EoE, irrespective of study location, prevalence of H. pylori in the population, time period, or whether studies were performed in pediatric or adult population.⁵²

There are several proposed mechanisms as to how H. pylori infection in children could reduce the risk of asthma and allergies. It has been shown that the Tregs induced by H. pylori were able to skew adaptive immune response toward immune tolerance.⁵³ Other mechanisms include regulating Th1/Th2 and Th17/Tregs balance, inhibition of dendritic cells and Heat shock protein 70, activation of Toll-like receptors, reduction of gastroesophageal reflux, hygiene hypothesis, and gut–lung axis theory.⁵⁴ However, others have concluded that H. pylori is inversely related to good hygiene and its presence just serves as a biomarker rather than any specific prevention role for H. pylori or H. pylori antigens.⁴⁷ Also, research on molecular mechanisms of the “hygiene hypothesis” and genetic analysis have highlighted that the allergies and asthma are not due to a single mechanism but multifactorial diseases with complex interplay between the organism and environment.⁵⁵

Inflammatory bowel disease

The incidence and prevalence of inflammatory bowel disease (IBD) is increasing worldwide, both in pediatric and adult populations.^56,57 A steady rise in the incidence of IBD is observed in H. pylori endemic regions, which corresponds to the beginning of anti-H. pylori therapy for PUD.⁵⁸ Although a small number of studies reported no association between H. pylori and IBD, the overwhelming majority of the studies to date, both epidemiological and basic experimental, strongly suggest a protective role of H. pylori infection against IBD. Luther et al. reported a protective effect of H. pylori against IBD in their meta-analysis and systematic review.⁵⁹ Sonnenberg and Genta compared the presence of H. pylori in more than 1000 IBD subjects with 65,000 control subjects and found that control subjects harbored H. pylori twice as frequently as IBD patients, confirming an inverse association between H. pylori and IBD.⁶⁰ Several meta-analyses and systematic reviews subsequently have confirmed this significant negative association between H. pylori and IBD, both in the pediatric and adult populations.^61–67 Kayali et al. reported a striking inverse association between H. pylori and IBD prevalence, independent of IBD subtypes and geographical regions.⁶³ Others reported evidence of H. pylori conferring more protection against Crohn’s compared to UC and also more protective effect in East Asian population compared to Mediterranean regions,⁶⁷ nonetheless protective against any type of IBD. Roka et al. observed that the occurrence of H. pylori gastritis is less frequent in children with IBD compared to controls.⁶⁸ It has also been shown that H. pylori is associated with less fistulizing and less active colitis in patients with Crohn’s disease.⁶⁹ A study from Taiwan, where H. pylori infection rate approaches 80% in the general population, reported that the treatment of H. pylori infection was associated with a significant increase in the risk of autoimmune diseases including IBD.⁷⁰ As opposed to this, a recent study, utilizing a large electronic medical records database from 26 major integrated health-care systems in the United States, showed that H. pylori eradication therapy is not associated with the development of IBD in the first 5 years after therapy, but it did confirm lower prevalence of IBD in the presence of H. pylori.⁷¹ Studies indicate that H. pylori colonization reduces the risk of IBD by 38–52%!^61,62

It could be argued that this protective effect may just be apparent rather than real, just an epidemiological association, reflecting the “hygiene hypothesis,” H. pylori being a surrogate marker for other phenomena such as reduced infections and improved socioeconomic conditions. But then, a systematic review and meta-analysis found that the closely related bacteria including enterohepatic Helicobacter species and campylobacter species increase the risk of IBD, suggesting an immunomodulatory effect specific to H. pylori.⁷² Similarly, another systematic review of gastrointestinal infections and incident IBD found that Salmonella species, Campylobacter species, and Clostridioides difficile demonstrated consistent positive association with the risk of incident IBD, whereas H. pylori and helminth infections were associated with a reduced risk of IBD.⁷³ This protective role of H. pylori is replicated in several animal studies and in vitro experimental studies too. Mice that were colonized with H. pylori prior to the induction of Salmonella typhimurium experimental colitis experienced markedly less severe inflammation compared to mice that were not colonized with H. pylori.⁷⁴ It has also been shown that prior oral administration of 20–50 μg H. pylori DNA ameliorated the severity of dextran sulfate-sodium-induced acute or chronic colitis in mice, in terms of both pathology and symptoms such as bleeding and weight loss.⁷⁵ This protective effect could be attributed to H. pylori-induced systemic immune tolerance and suppression of inflammatory response. Tolerogenic phenotype dendritic cells and immunosuppressive Tregs are thought to be involved in this protective mechanism.^76–78 Taking all these into consideration, it could be argued strongly that H. pylori is a potent modulator of the immune system and prevents IBD.

Gastroesophageal reflux disease, Barrett’s esophagus, and esophageal adenocarcinoma

Several epidemiological studies have demonstrated a negative association between H. pylori and gastroesophageal reflux disease (GERD) and related complications like Barrett’s esophagus and esophageal adenocarcinoma in the adult population. Just about two decades after the discovery of H. pylori, a systematic review found that the prevalence of H. pylori infection was significantly lower in those with gastroesophageal reflux than those without.⁷⁹ This inverse relationship between GERD and H. pylori has been reported in several subsequent studies.⁸⁰ This is also true for Barrett’s esophagus and esophageal adenocarcinoma.^81–83 The relationship between H. pylori and GERD is not as clear cut in the pediatric population however. Some studies reported higher prevalence of reflux esophagitis in H. pylori-infected children^84,85 and others reported the contrary.^86,87 The reason for this disparity may lie in that the determinants affecting GERD in H. pylori are the location of gastric inflammation and CagA positivity in both children and adults.⁸⁸ It is well established that gastric acid secretion is a key factor in the pathophysiology of reflux esophagitis. Depending on the type of gastritis related to H. pylori, acid secretion may either increase or decrease. Gastritis in corpus leads to hypoacidity, while antrum gastritis leads to hyperacidity. In adults, HP infection is often associated with atrophic gastritis in the corpus, whereas in children, it is often associated with antral predominant gastritis. Depending on the type of gastritis, the H. pylori eradication may either aggravate or alleviate GERD.

Obesity

Obesity has become a major public health problem of global significance. The incidence of obesity in the general population has skyrocketed during the past 20 years, and more than doubled in children and quadrupled in adolescents in the past 30 years. Clearly, the most important risk factors are related to changes in the diet and lifestyle. Interestingly, an inverse relation with H. pylori infection has been reported by many studies, both in the adult and pediatric populations.^89–91 It has been postulated that H. pylori-induced gastritis modulates the levels of gastric hormones, ghrelin and leptin, that influence eating behavior. Ghrelin secreted by the stomach is an appetite-stimulating hormone. H. pylori is found to decrease ghrelin secretion by reducing the number of gastric ghrelin-producing cells.⁹² Leptin, on the other hand, is an anorexigenic hormone. Though mainly produced by adipose tissue, it is also synthesized in the stomach. H. pylori infection upregulates gastric leptin secretion.⁸⁹ It has been shown that long-term eradication of H. pylori infection is associated with a significant increase in body mass index, lean, and fat mass along with a significant decrease in circulating ghrelin levels and an increase in leptin levels in prepubertal children.⁹³

Discussion

There is increasing evidence suggesting beneficial role of H. pylori with several studies, systematic reviews, and meta-analyses showing an inverse association between H. pylori and various chronic health conditions, as discussed above. It could be argued, quite rightly, that these inverse associations could just reflect the significant socioeconomic improvements and the lifestyle changes seen in recent decades with improved sanitation, reduced infections, dietary habits, etc., H. pylori being just a surrogate marker of this. But then, several experimental studies directly showing potential benefits of H. pylori cannot be ignored. On the one hand, H. pylori is clearly demonstrated to cause PUD and gastric cancers, albeit, in a minority of the infected population. On the other hand, several epidemiological and experimental studies demonstrate beneficial aspects of this bacterium against various human health conditions. It is important to remember that H. pylori has coevolved with humans for several thousands of years. Though more than half of world’s population is infected, clinical disease occurs only in a small proportion of the infected subjects. The majority of the infected individuals show histologic chronic gastritis even though asymptomatic,⁹⁴ but only a small fraction of infected individuals develop H. pylori-associated diseases such as PUD and more rarely gastric carcinomas.⁹⁵ It has been estimated that the H. pylori infection is linked to gastric and duodenal ulcers in 1–10% of infected patients, gastric carcinoma in 0.1–0.3%, and gastric MALT lymphoma in less than 0.01%.⁹⁶ Therefore, there is an alternative point of view that H. pylori may be considered as a commensal symbiont, part of normal human stomach microbiome.^97–100 Unlike other pathogenic bacteria, H. pylori colonization in infancy leads to the development of immune tolerance.⁹⁸ Just as we do not attempt to eradicate the gut microbiome, so should be H. pylori, to be treated only if it causes problem, which, we know, happens only in a small minority of infected subjects.

In contrast to the pediatric guidelines, adult guidelines to date have recommended eradication of H. pylori in all patients with infection, regardless of the presence of PUD or background risk of gastric cancer. Interestingly however, in recent years, there has been increasing recognition of the beneficial role of H. pylori. Many experts have now questioned the unconditional recommendation to eradicate H. pylori in every case. Instead, they call for a more individualized treatment approach in the context of additional risk factors.^{97,98,101,102}

From a practical point of view, what does this mean for pediatricians and pediatric gastroenterologists? On the face of it, it is simple enough, just follow the guidelines – do not “test and treat.” What do we do, if during investigation of child’s symptom, H. pylori is detected? Available evidence would suggest not to eradicate unless ulcer disease is present. Of course, this would need to be discussed with the family, explaining the rationale for the decision not to treat (or treat). What is not clear at present is, how long and how often the children in whom decision is made not to treat, should be followed up.¹⁶ In part, this would be dependent on the background risk of gastric cancer in the population, but further longitudinal studies are needed to address this. For now, however, when you next encounter a child with H. pylori infection/gastritis but no PUD, let it not trigger an automatic eradication treatment prescription but rather consider leaving H. pylori alone, taking into account the probable beneficial effects of H. pylori as discussed above and the low-frequency complications in children.

Conclusion

The decision to treat H. pylori infection in children should be based on providing true benefit and do no harm. No doubt, eradication treatment needs to be undertaken in children with PUD but not in every child in whom H. pylori is detected. The aim of this review is not to dispute the fact that H. pylori is a class 1 human carcinogen and is etiologically related to gastric and duodenal ulcers, gastric cancer, and mucosa-associated lymphoid tissue lymphoma but to draw reader’s attention to possible beneficial effects H. pylori may confer against asthma, allergies, EoE, and IBD especially in childhood. There appears to be increasing evidence base for these beneficial effects of H. pylori. Various molecular mechanisms have been elucidated to explain these beneficial effects; detailed description of these is beyond the scope of this review.

Footnotes

Acknowledgements

None.

Declarations

ORCID iD

M. Ravikumara

References

Hooi

JKY

Lai

, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology 2017; 153: 420–429.

Yuan

Adeloye

Luk

, et al. The global prevalence of and factors associated with Helicobacter pylori infection in children: a systematic review and meta-analysis. Lancet 2022; 6: 185–194.

Salama

Hartung

Müller

Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori. Nat Rev Microbiol 2013; 11: 385–399.

Warren

Marshall

Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; 1: 1273–1275.

Ford

Gurusamy

Delaney

, et al. Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people. Cochrane Database Syst Rev 2016; 4: CD003840.

Yan

Chen

, et al. Effect of Helicobacter pylori eradication on Gastric Cancer Prevention: updated report from a randomized controlled trial with 26.5 years of follow-up. Gastroenterology 2022; 163: 154–162.e3. e3.

Yuan

YUMIN

Yang

KEHU

, et al. Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials. Scand J Gastroenterol 2010; 45: 665–676.

Huang

Xiong

, et al. Does Helicobacter pylori infection play a role in iron deficiency anemia? A meta-analysis. World J Gastroenterol 2010; 16: 886–896.

Huang

Yan

, et al. Iron deficiency anaemia can be improved after eradication of Helicobacter pylori. Postgrad Med J 2010; 86: 272–278.

10.

Franchini

Cruciani

Mengoli

, et al. Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic purpura: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 60: 237–246.

11.

Ražuka-Ebela

Giupponi

Franceschi

Helicobacter pylori and extragastric diseases. Helicobacter 2018; 23 Suppl 1: e12520.

12.

Liu

Ouyang

, et al. Helicobacter pylori and unignorable extragastric diseases: mechanism and implications. Front Microbiol 2022; 13: 972777.

13.

Chey

Leontiadis

Howden

, et al. ACG clinical guideline: Treatment of Helicobacter pylori infection. Am J Gastroenterol 2017; 112: 212–239.

14.

Sugano

Tack

Kuipers

, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64: 1353–1367.

15.

Malfertheiner

Megraud

O’Morain

, et al. Management of Helicobacter pylori infection-the maastricht V/Florence Consensus Report. Gut 2017; 66: 6–30.

16.

Hojsak

Kolacek

Is Helicobacter pylori always a “bad guy”?

Curr Pharm Des 2014; 20: 4517–4520.

17.

Nasri

Saneian

Famouri

, et al. Helicobacter pylori infection in pediatrics with gastrointestinal complaints. Int J Physiol Pathophysiol Pharmacol 2022; 14: 118–123.

18.

Spee

Madderom

Pijpers

, et al. Association between helicobacter pylori and gastrointestinal symptoms in children. Pediatrics 2010; 125: e651–e669.

19.

Dore

Fanciulli

Tomasi

, et al. Gastrointestinal symptoms and Helicobacter pylori infection in school-age children residing in Porto Torres, Sardinia, Italy. Helicobacter 2012; 17: 369–373.

20.

Chobot

Porębska

Krzywicka

, et al. No association between Helicobacter pylori infection and gastrointestinal complaints in a large cohort of symptomatic children. Acta Paediatr 2019; 108: 1535–1540.

21.

Jaime

Villagrán

Hernández

, et al. Functional gastrointestinal disorders in children from low socio-economic status and Helicobacter pylori infection. Child Care Health Dev 2018; 44: 319–325.

22.

Hojsak

Kos

Dumančić

, et al. Antibiotic resistance of Helicobacter pylori in pediatric patients – 10 years’ experience. Eur J Pediatr 2012; 171: 1325–1330.

23.

Koletzko

Richy

Bontems

, et al. Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut 2006; 55: 1711–1716.

24.

Jansson

Agardh

Prevalence of clarithromycin-resistant Helicobacter pylori in children living in south of Sweden: a 12-year follow-up. Scand J Gastroenterol 2019; 54: 838–842.

25.

Jones

Koletzko

Goodman

, et al. Joint ESPGHAN/NASPGHAN guidelines for the management of Helicobacter pylori in children and adolescents (Update 2016). J Pediatr Gastroenterol Nutr 2017; 64: 991–1003.

26.

Bonilla

Mitchell

Mansuri

Low adherence to society guidelines for the management of Helicobacter pylori among pediatric gastroenterologists. J Pediatr Gastroenterol Nutr 2021; 73: 178–183.

27.

Hansen

Evjenth

Holt

Increasing prevalence of asthma, allergic rhinoconjunctivitis and eczema among schoolchildren: three surveys during the period 1985-2008. Acta Paediatr 2013; 102: 47–52.

28.

Serebrisky

Wiznia

Pediatric Asthma: A Global Epidemic. Ann Global Health 2019; 85: 6, 1–6.

29.

Bach

JF.

The effect of infections on susceptibility to autoimmune and allergic diseases. New Engl J Med 2002; 347: 911–920.

30.

Kalach

Bontems

Raymond

Helicobacter pylori infection in children. Helicobacter 2017; 22(Suppl. 1): e12414.

31.

Rowland

The continuing decline in the prevalence of Helicobacter pylori infection. Lancet Child Adolesc Health 2022; 6: 139–140.

32.

Leja

Grinberga-Derica

Bilgilier

, et al. Review: Epidemiology of Helicobacter pylori infection. Helicobacter 2019; 24(Suppl. 1): e12635.

33.

Chen

Blaser

MJ.

Helicobacter pylori colonization is inversely associated with childhood asthma. J Infect Dis 2008; 198: 553–560.

34.

Chen

Zhan

Wang

Association between Helicobacter pylori and risk of childhood asthma: a meta-analysis of 18 observational studies. J Asthma 2022; 59: 890–900.

35.

Elias

Nasrallah

Khoury

, et al. Associations of Helicobacter pylori seropositivity and gastric inflammation with pediatric asthma. Pediatr Pulmonol 2020; 55: 2236–2245.

36.

Zevit

Balicer

Cohen

, et al. Inverse association between Helicobacter pylori and pediatric asthma in a high-prevalence population. Helicobacter 2012; 17: 30–35.

37.

Wang

Chen

Ding

, et al. Inverse association between Helicobacter pylori infection and childhood asthma in a physical examination population: a cross-sectional study in Chongqing, China. BMC Pediatr 2022; 22: 615.

38.

Fouda

Kamel

Nabih

, et al. Helicobacter pylori seropositivity protects against childhood asthma and inversely correlates to its clinical and functional severity. Allergol Immunopathol 2018; 46: 76–81.

39.

Chen

Xun

Tsinovoi

, et al. Accumulated evidence on Helicobacter pylori infection and the risk of asthma: a meta-analysis. Ann Allergy Asthma Immunol 2017; 119: 137–145.e2. e2.

40.

Amberbir

Medhin

Abegaz

, et al. Exposure to Helicobacter pylori infection in early childhood and the risk of allergic disease and atopic sensitization: a longitudinal birth cohort study. Clin Exp Allergy 2014; 44: 563–571.

41.

Lionetti

Leonardi

Lanzafame

, et al. Helicobacter pylori infection and atopic diseases: is there a relationship? A systematic review and meta-analysis. World J Gastroenterol 2014; 20: 17635–17647.

42.

Taye

Enquselassie

Tsegaye

, et al. Is Helicobacter Pylori infection inversely associated with atopy? A systematic review and meta-analysis. Clin Exp Allergy 2015; 45: 882–890.

43.

Pedullà

Fierro

Del Tufo

, et al. Helicobacter pylori immunization and atopic dermatitis in South Italian children. United Eur Gastroenterol J 2014; 2: 263–267.

44.

Arnold

Dehzad

Reuter

, et al. Helicobacter pylori infection prevents allergic asthma in mouse models through the induction of regulatory T cells. J Clin Investig 2011; 121: 3088–3093.

45.

Oertli

Müller

Helicobacter pylori targets dendritic cells to induce immune tolerance, promote persistence and confer protection against allergic asthma. Gut Microbes 2012; 3: 566–571.

46.

Oertli

Sundquist

Hitzler

, et al. DC-derived IL-18 drives Treg differentiation, murine Helicobacter pylori-specific immune tolerance, and asthma protection. J Clin Investig 2012; 122: 1082–1096.

47.

Miftahussurur

Nusi

Graham

, et al. Helicobacter, hygiene, atopy, and asthma. Front Microbiol 2017; 8: 1034.

48.

Dowling

Neuhaus

Polk

BI.

The role of the environment in Eosinophilic Esophagitis. Clin Rev Allergy Immunol 2019; 57: 330–339.

49.

Furuta

Adachi

Aimi

, et al. Case-control study of association of eosinophilic gastrointestinal disorders with Helicobacter pylori infection in Japan. J Clin Biochem Nutr 2013; 53: 60–62.

50.

O’Shea

Aceves

Dellon

, et al. Pathophysiology of eosinophilic esophagitis. Gastroenterology 2018; 154: 333–345.

51.

Elitsur

Alrazzak

Preston

, et al. Does Helicobacter pylori protect against eosinophilic esophagitis in children? Helicobacter 2014; 19: 367–371.

52.

Shah

Tepler

Peek

Jr , et al. Association between Helicobacter pylori exposure and decreased odds of eosinophilic Esophagitis-A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2019; 17: 2185–2198.e3.

53.

Arnold

Hitzler

Müller

The immunomodulatory properties of Helicobacter pylori confer protection against allergic and chronic inflammatory disorders. Front Cell Infect Microbiol 2012; 2: 10.

54.

Zuo

Sun

, et al. The protective effects of Helicobacter pylori infection on allergic asthma. Int Arch Allergy Immunol 2021; 182: 53–64.

55.

Vercelli

Mechanisms of the hygiene hypothesis – molecular and otherwise. Curr Opin Immunol 2006; 18: 733–737.

56.

Kuenzig

Fung

Marderfeld

, et al. Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review. Gastroenterology 2022; 162: 1147–1159.e4. e4.

57.

Shi

Hamidi

, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017; 390: 2769–2778.

58.

Thia

Loftus

Jr. Sandborn

, et al. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol 2008; 103: 3167–3182.

59.

Luther

Dave

Higgins

, et al. Association between Helicobacter pylori infection and inflammatory bowel disease: a meta-analysis and systematic review of the literature. Inflamm Bowel Dis 2010; 16: 1077–1084.

60.

Sonnenberg

Genta

RM.

Low prevalence of Helicobacter pylori infection among patients with inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 469–476.

61.

Rokkas

Gisbert

Niv

, et al. The association between Helicobacter pylori infection and inflammatory bowel disease based on meta-analysis. United Eur Gastroenterol J 2015; 3: 539–550.

62.

Yang

, et al. Helicobacter pylori infection and inflammatory bowel disease in Asians: a meta-analysis. World J Gastroenterol 2015; 21: 4750–4756.

63.

Kayali

Gaiani

Manfredi

, et al. Inverse association between Helicobacter pylori and inflammatory bowel disease: myth or fact? Acta Biomed 2018; 89: 81–86.

64.

Tepler

Narula

Peek

Jr , et al. Systematic review with meta-analysis: association between Helicobacter pylori CagA seropositivity and odds of inflammatory bowel disease. Aliment Pharmacol Ther 2019; 50: 121–131.

65.

Shirzad-Aski

Besharat

Kienesberger

, et al. Association between Helicobacter pylori colonization and inflammatory bowel disease: a systematic review and meta-analysis. J Clin Gastroenterol 2021; 55: 380–392.

66.

Zhong

Zhang

Lin

, et al. The relationship between Helicobacter pylori and inflammatory bowel disease. Arch Iran Med 2021; 24: 317–325.

67.

Imawana

Smith

Goodson

ML.

The relationship between inflammatory bowel disease and Helicobacter pylori across East Asian, European and Mediterranean countries: a meta-analysis. Ann Gastroenterol 2020; 33: 485–494.

68.

Roka

Roubani

Stefanaki

, et al. The prevalence of Helicobacter pylori gastritis in newly diagnosed children with inflammatory bowel disease. Helicobacter 2014; 19: 400–405.

69.

Fialho

Nassri

, et al. Helicobacter pylori is associated with less fistulizing, stricturing, and active colitis in Crohn’s disease patients. Cureus 2019; 11: e6226.

70.

Lin

Chiu

Waljee

, et al. Effects of anti–Helicobacter pylori therapy on incidence of autoimmune diseases, including inflammatory bowel diseases. Clin Gastroenterol Hepatol 2019; 17: 1991–1999.

71.

Tanner

Katz

Cominelli

, et al. Inflammatory bowel disease and Helicobacter pylori: protective or present? Inflamm Bowel Dis. Epub ahead of print 28 September 2022. DOI: 10.1093/ibd/izac202.

72.

Castaño-Rodríguez

Kaakoush

Lee

, et al. Dual role of Helicobacter and Campylobacter species in IBD: a systematic review and meta-analysis. Gut 2017; 66: 235–249.

73.

Axelrad

Cadwell

Colombel

, et al. Systematic review: gastrointestinal infection and incident inflammatory bowel disease. Aliment Pharmacol Ther 2020; 51: 1222–1232.

74.

Higgins

Johnson

Luther

, et al. Prior Helicobacter pylori infection ameliorates Salmonella typhimurium-induced colitis: mucosal crosstalk between stomach and distal intestine. Inflamm Bowel Dis 2011; 17: 1398–1408.

75.

Luther

Owyang

Takeuchi

, et al. Helicobacter pylori DNA decreases pro-inflammatory cytokine production by dendritic cells and attenuates dextran sodium sulphate-induced colitis. Gut 2011; 60: 1479–1486.

76.

Zhu

, et al. Helicobacter pylori infection and inflammatory bowel disease: a crosstalk between upper and lower digestive tract. Cell Death Dis 2018; 9: 961.

77.

Papamichael

Konstantopoulos

Mantzaris

GJ.

Helicobacter pylori infection and inflammatory bowel disease: is there a link?

World J Gastroenterol 2014; 20: 6374–6385.

78.

Arnold

Müller

Helicobacter pylori: does gastritis prevent colitis?

Inflamm Intest Dis 2016; 1: 102–112.

79.

Raghunath

Hungin

Wooff

, et al. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ 2003; 326: 737.

80.

Scida

Russo

Miraglia

, et al. Relationship between Helicobacter pylori infection and GERD. Acta Biomed 2018; 89: 40–43.

81.

Wang

Shaheen

Whiteman

, et al. Helicobacter pylori infection is associated with reduced risk of Barrett’s Esophagus: An Analysis of the Barrett’s and Esophageal Adenocarcinoma Consortium. Am J Gastroenterol 2018; 113: 1148–1155.

82.

Duan

LP.

Helicobacter pylori infection is associated with reduced risk of Barrett’s esophagus: a meta-analysis and systematic review. BMC Gastroenterol 2021; 21: 459.

83.

Guo

Wang

, et al. Association of Barrett’s esophagus with Helicobacter pylori infection: a meta-analysis. Ther Adv Chronic Dis 2022; 13: 20406223221117971.

84.

Moon

Solomon

Beneck

, et al. Positive association between Helicobacter pylori and gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2009; 49: 283–288.

85.

Daugule

Rumba

Alksnis

, et al. Helicobacter pylori infection among children with gastrointestinal symptoms: a high prevalence of infection among patients with reflux oesophagitis. Acta Paediatr 2007; 96: 1047–1049.

86.

Gold

BD.

Outcomes of pediatric gastroesophageal reflux disease: in the first year of life, in childhood, and in adults. . .oh, and should we really leave Helicobacter pylori alone?

J Pediatr Gastroenterol Nutr 2003; 37(Suppl 1): S33–S39.

87.

Abdollahi

Morteza

Khalilzadeh

, et al. The role of Helicobacter pylori infection in gastro-oesophageal reflux in Iranian children. Ann Trop Paediatr 2011; 31: 53–57.

88.

Yucel

Interactions between Helicobacter pylori and gastroesophageal reflux disease. Esophagus 2019; 16: 52–62.

89.

Goli

Gill

, et al. Inverse Correlation Between Helicobacter pylori Colonization and obesity in a cohort of inner city children. Helicobacter 2015; 20: 64–68.

90.

Moran-Lev

Lubetzky

Mandel

, et al. Inverse correlation between Helicobacter pylori colonization and pediatric overweight: a preliminary study. Child Obes 2017; 13: 267–271.

91.

Lender

Talley

Enck

, et al. Review article: associations between Helicobacter pylori and obesity – an ecological study. Aliment Pharmacol Ther 2014; 40: 24–31.

92.

Tatsuguchi

Miyake

Gudis

, et al. Effect of Helicobacter pylori infection on ghrelin expression in human gastric mucosa. Am J Gastroenterol 2004; 99: 2121–2127.

93.

Pacifico

Anania

Osborn

, et al. Long-term effects of Helicobacter pylori eradication on circulating ghrelin and leptin concentrations and body composition in prepubertal children. Eur J Endocrinol 2008; 158: 323–332.

94.

Dooley

Cohen

Fitzgibbons

, et al. Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons. New Engl J Med 1989; 321: 1562–1566.

95.

Cover

Blaser

MJ.

Helicobacter pylori in health and disease. Gastroenterology 2009; 136: 1863–1873.

96.

McColl

KE.

Clinical practice: Helicobacter pylori infection. New Engl J Med 2010; 362: 1597–1604.

97.

Reshetnyak

Burmistrov

Maev

IV.

Helicobacter pylori: commensal, symbiont or pathogen?

World J Gastroenterol 2021; 27: 545–560.

98.

Sitkin

Lazebnik

Avalueva

, et al. Gastrointestinal microbiome and Helicobacter pylori: eradicate, leave it as it is, or take a personalized benefit-risk approach? World J Gastroenterol 2022; 28: 766–774.

99.

Blaser

MJ.

Helicobacter pylori and gastric diseases. BMJ 1998; 316: 1507–1510.

100.

Blaser

MJ.

Helicobacters are indigenous to the human stomach: duodenal ulceration is due to changes in gastric microecology in the modern era. Gut 1998; 43: 721–727.

101.

Schubert

Rayner

Costello

, et al. Helicobacter pylori: have potential benefits been overlooked? JGH Open 2022; 6: 735–737.

102.

Desai

Edhi

Hakim

. Eradicating H. pylori. Am J Gastroenterol 2019; 114: 1827–1828.